full safety disclaimer<\/a>.<\/em><\/p>\nThe Monti 2019 Study<\/h2>\n
Of all 29 compounds in our Parkinson’s mechanism analysis (Project 12), N-Acetyl Cysteine (NAC) has the strongest published clinical evidence. The Monti et al. 2019 study (PMID: 31048906) enrolled 42 Parkinson’s patients and found that those receiving NAC alongside standard care showed improved dopamine transporter (DaT) binding on brain imaging and better clinical outcomes on the UPDRS scale.<\/p>\n
Our V3 Known Properties Report grades NAC at B+ for Parkinson’s \u2014 the highest grade in any of our four research packages. But that grade comes with important caveats.<\/p>\n
The Limitations<\/h2>\n
The Monti study was open-label with no placebo group. 42 patients is a small sample. The patients receiving NAC also received IV infusions, which is not the same as oral supplementation. No large randomized controlled trial has confirmed these findings.<\/p>\n
We downgraded NAC from Grade A to B+ in our V3 report specifically because of these limitations. Being honest about evidence quality is more important than being optimistic.<\/p>\n
Iron: A Cautionary Tale<\/h2>\n
Our analysis also flagged iron as mechanism-relevant for Parkinson’s. But the FAIR PARK-II trial (n=372) tested deferiprone for iron chelation in early Parkinson’s \u2014 and it failed. Patients in the treatment group did worse. This is why computational analysis cannot replace clinical trials.<\/p>\n
The full research package includes all of this context: the promising leads, the failures, and the safety warnings.<\/p>\n
Download the full Parkinson’s research package (free).<\/a><\/p>\n[\/lcus_masonry_article]<\/p>\n
<\/p>\n
\n